ARWR
Arrowhead Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +7.0% · netto nieuwe posities -5.6% · formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 25.13K | $1.54M | n/a | n/a |
| Q2 2026 | 131 | +6 | 82.23M | $6.28B | +14 | −9 |
| Q1 2026 | 129 | +9 | 82.68M | $4.92B | +14 | −6 |
| Q4 2025 | 119 | +2 | 83.16M | $5.52B | +3 | n/a |
| Q3 2025 | 18 | 0 | 61.93M | $2.14B | +1 | −2 |
| Q2 2025 | 16 | +2 | 54.75M | $865.08M | +2 | n/a |
| Q1 2025 | 11 | +1 | 14.99M | $191.04M | +1 | n/a |
| Q4 2024 | 10 | -1 | 13.46M | $253.12M | +1 | −2 |
| Q3 2024 | 10 | +1 | 7.88M | $152.69M | +1 | n/a |
| Q2 2024 | 9 | n/a | 6.44M | $167.29M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 20.22M | +4.1% | $697.55M | 0.0% | ▲ Add | 2 | SEC ↗ ×17 |
| 2 | The Vanguard Group ✦ (passief) | 16.04M | +3.3% | $553.08M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passief) | 6.40M | +0.4% | $220.65M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Fidelity (FMR) ✦ | 5.76M | +11.4% | $198.66M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 5 | Geode Capital Management ✦ (passief) | 3.13M | +5.1% | $108.01M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Arrowstreet Capital ✦ | 2.08M | +3142.5% | $71.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Goldman Sachs Group ✦ | 1.77M | n/a | $61.18M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Morgan Stanley ✦ | 1.70M | n/a | $58.73M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 9 | JPMorgan Chase ✦ | 1.55M | n/a | $53.51M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 10 | Marshall Wace ✦ | 1.44M | -33.4% | $49.56M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 11 | Fisher Asset Management ✦ | 1.05M | +133.3% | $36.35M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 317.61K | +410.3% | $10.95M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 142.82K | -6.2% | $4.93M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 14 | T. Rowe Price ✦ | 110.25K | +9.6% | $3.80M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | Millennium Management ✦ | 109.81K | -35.0% | $3.79M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | Wellington Management ✦ | 49.44K | +2.4% | $1.71M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 17 | Gotham Asset Management ✦ | 31.86K | +68.9% | $1.10M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | D. E. Shaw & Co. ✦ | 20.30K | Nieuw | $700,181 | 0.0% | New | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| D. E. Shaw & Co. | $700,181 | 0.0% |
Verlaten
| Norges Bank | $30.41M | was 0.0% |
| Two Sigma Investments | $2.11M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 430 houders, 120.06M aandelen, $7.40B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Director · 2.00K aand · $173,920
Director · 11.60K aand · $1.01M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie